Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study

OBJECTIVES: IGU (IGU), a novel immunomodulatory agent for rheumatoid arthritis, has been shown to be effective and safe as monotherapy in a small population with refractory lupus nephritis (LN). The aim of this prospective study was to evaluate the efficacy and safety of IGU as an add-on therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Qingran, Zhang, Mei, Du, Fang, Kang, Yuening, Ye, Ping, Li, Qianqian, Liu, Bei, Dai, Min, Bao, Chunde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030952/
https://www.ncbi.nlm.nih.gov/pubmed/36969217
http://dx.doi.org/10.3389/fimmu.2023.1062919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030952/
https://www.ncbi.nlm.nih.gov/pubmed/36969217
http://dx.doi.org/10.3389/fimmu.2023.1062919

Ejemplares similares